Umbilical cord blood stem cells: clinical trials in non-hematological disorders

Ilić, Duško; Miere, Cristian; Lazic, Emilija

doi:10.1093/bmb/lds008

Cited by 43 publications

(27 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have high levels of telomerase activity based upon their proliferative potential in human umbilical cord blood [33]. However, UCB is routinely used for hematopoietic stem cell transplantation in order to treat haematological conditions for a wide range of diseases but it can be used for regenerative cellular based treatment and immunomodulation [25,34,35]. There are some clinical studies that have already been done and some of them have been halted for some issues [25].…”

Section: Isolated Cell Types From Cord Bloodmentioning

confidence: 99%

Stem Cells in Regenerative Medicine: Prospects and Pitfalls

Zehravi¹,

Shahid²,

Kashmala³

et al. 2017

Natl. j. health sci.

View full text Add to dashboard Cite

Stem cells are the cells that have the ability to regenerate themselves and are able to differentiate into one or more specialized cell types. This unique property makes them a valuable source for in vitro disease modeling, drug designing, regenerative medicine and tissue engineering. As no specie can fully mimic the human microenvironment, human cell models derived from patients cells provide a fascinating avenue for enhancing our current understanding of the early molecular stages of various diseases followed by validating therapeutics. In this paper, we reviewed the role of stem cells in regenerative medicine that includes use of cord blood derived stem cells in medicine and patient specific induced pluripotent stem cells for future transplant purposes and the hurdles and obstacles that we need to address before we can safely use these cells for patient cure.

show abstract

Section: Isolated Cell Types From Cord Bloodmentioning

confidence: 99%

Stem Cells in Regenerative Medicine: Prospects and Pitfalls

Zehravi¹,

Shahid²,

Kashmala³

et al. 2017

Natl. j. health sci.

View full text Add to dashboard Cite

show abstract

“…Limited clinical trials of hUCB cells for stroke are ongoing, as well as in the treatment of other neurological disorders [for review see 27]. There are several advantages to using hUCB in cell transplantation therapy such as providing an unlimited supply of cells in culture thereby circumventing ethical and logistical issues, availability in significant quantities and producing higher yields of hematopoietic progenitor cells, retained capacity of stem or progenitor cell from cord blood to proliferate and differentiate despite years of cryopreservation, low incidence of graft-versus-host disease when compared to that of the adult bone marrow, and long-standing and successful clinical history in the hematopoietic field [for review see 28].…”

Section: Stem Cells For Stroke Treatmentmentioning

confidence: 99%

Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke

Peña

Borlongan

2015

Transl. Stroke Res.

View full text Add to dashboard Cite

Among recently investigated stroke therapies, stem cell treatment holds great promise by virtue of their putative ability to replace lost cells, promote endogenous neurogenesis and produce behavioral and functional improvement through their “bystander effects.” Translating stem cell in the clinic, however, presents a number of technical difficulties. A strategy suggested to enhance therapeutic utility of stem cells is combination therapy, i.e., cotransplantation of stem cells or adjunct treatment with pharmacological agents and substrates, which is assumed to produce more profound therapeutic benefits by circumventing limitations of individual treatments, and facilitating complementary brain repair processes. We previously demonstrated enhanced functional effects of co-treatment with granulocyte-colony stimulating factor (G-CSF) and human umbilical cord blood cell (hUCB) transplantation in animal models of traumatic brain injury (TBI). Here, we suggest that the aforementioned combination therapy may also produce synergistic effects in stroke. Accordingly, G-CSF treatment may reduce expression of pro-inflammatory cytokines and enhance neurogenesis rendering a receptive microenvironment for hUCB engraftment. Adjunct treatment of G-CSF with hUCB may facilitate stemness maintenance and guide neural lineage commitment of hUCB cells. Moreover, regenerative mechanisms afforded by G-CSF-mobilized endogenous stem cells, secretion of growth factors by hUCB grafts and G-CSF-recruited endothelial progenitor cells (EPCs) , as well as the potential graft–host integration that may promote synaptic circuitry re-establishment could altogether produce more pronounced functional improvement in stroked rats subjected to a combination G-CSF treatment and hUCB transplantation. Nevertheless, differences in pathology and repair processes underlying TBI and stroke deserve consideration when testing effects of combinatorial G-CSF and hUCB cell transplantation for stroke treatment. Further studies are also required to determine safety and efficacy of this intervention in both preclinical and clinical stroke studies.

show abstract

“…Clinical trials using allogeneic UCB are currently in progress for a diverse range of diseases, including neurological disorders (Alzheimer's and cerebral palsy), inherited disorders (epidermolysis bullosa), autoimmune disorders (autism, diabetes, systemic lupus erythematosus and systemic sclerosis), preterm birth defects (bronchopulmonary dysplasia), cartilage injury (osteoarthritis), inborn metabolic disorders (mucopolysaccharidoses and hurler syndrome), critical limb ischemia, autosomal recessive osteopetrosis, solid tumors, stroke and burns [85]. The use of ex vivo-expanded Tregs has also proven to improve clinical outcomes in Type 1 diabetes [36].…”

Section: Clinical Applications Of Hsctmentioning

confidence: 99%

Applications of Human Hematopoietic Stem Cells Isolated and Expanded from Different Tissues in Regenerative Medicine

Tripura

Pande

2013

Regen. Med.

View full text Add to dashboard Cite

Bone marrow transplantation is a well-established stem cell-based therapy for the management of malignant and nonmalignant hematological disorders. In addition to the bone marrow, therapeutic hematopoietic stem cells (HSCs) can also be obtained from umbilical cord blood and mobilized peripheral blood. Transplantation of HSCs isolated from these tissues can be carried out with or without prior enrichment of specific cell types. New methodologies have been developed for lineage-specific HSC expansion and their transplantation as a supplementary treatment to whole bone marrow transplantation. In this review we have described the current methodologies for isolating and processing HSCs from various tissues, and discussed strategies to generate sufficient and functional HSCs for clinical and preclinical applications by expansion ex vivo. The various disease conditions in which these cells could be used, and the methods for delivering the cells into patients, are also discussed.

show abstract

Umbilical cord blood stem cells: clinical trials in non-hematological disorders

Abstract: A need for standardization of criteria for selection of UCB units for stem cell-based therapy, outcome measures and long-term follow-up.

Cited by 43 publications

References 45 publications

Stem Cells in Regenerative Medicine: Prospects and Pitfalls

Stem Cells in Regenerative Medicine: Prospects and Pitfalls

Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke

Applications of Human Hematopoietic Stem Cells Isolated and Expanded from Different Tissues in Regenerative Medicine

Contact Info

Product

Resources

About